BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 711 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 711 shares of BioLife Solutions stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $22.23, for a total transaction of $15,805.53. Following the sale, the insider now owns 78,721 shares in the company, valued at $1,749,967.83. This represents a 0.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Sarah Aebersold also recently made the following trade(s):

• On Tuesday, June 10th, Sarah Aebersold sold 235 shares of BioLife Solutions stock. The stock was sold at an average price of $23.70, for a total transaction of $5,569.50.
• On Wednesday, May 28th, Sarah Aebersold sold 217 shares of BioLife Solutions stock. The stock was sold at an average price of $22.46, for a total transaction of $4,873.82.
• On Wednesday, April 9th, Sarah Aebersold sold 210 shares of BioLife Solutions stock. The shares were sold at an average price of $20.11, for a total value of $4,223.10.
• On Tuesday, April 1st, Sarah Aebersold sold 5,771 shares of BioLife Solutions stock. The shares were sold at an average price of $22.66, for a total value of $130,770.86.

BioLife Solutions Price Performance

Shares of BLFS opened at $21.52 on Thursday. BioLife Solutions, Inc. has a one year low of $18.70 and a one year high of $29.55. The stock’s fifty day moving average is $22.71 and its 200-day moving average is $24.85. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -74.20 and a beta of 1.82.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. The firm had revenue of $23.94 million during the quarter, compared to analyst estimates of $22.22 million. Equities analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Wall Street Analysts Forecast Growth

BLFS has been the subject of several analyst reports. Wall Street Zen downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Wednesday, May 21st. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Proficio Capital Partners LLC acquired a new stake in BioLife Solutions in the fourth quarter worth approximately $638,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of BioLife Solutions by 13.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider’s stock worth $1,835,000 after buying an additional 8,258 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of BioLife Solutions by 11.9% in the 4th quarter. Alliancebernstein L.P. now owns 37,351 shares of the medical equipment provider’s stock worth $970,000 after buying an additional 3,967 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of BioLife Solutions by 18.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 198,695 shares of the medical equipment provider’s stock valued at $5,158,000 after buying an additional 31,167 shares during the period. Finally, Victory Capital Management Inc. boosted its stake in BioLife Solutions by 422.2% during the fourth quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider’s stock valued at $5,684,000 after buying an additional 177,028 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.